{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:31:08Z","timestamp":1778103068481,"version":"3.51.4"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Patients with metastatic castration-resistant prostate cancer usually have lymph nodes and bone metastasis. We present a rare case of a 51-year-old patient with metastatic castration-resistant prostate cancer who complained of left truncated sciatica and diffuse bone pain and who was referred for <jats:sup>177<\/jats:sup>Lu-prostate-specific membrane antigen (PSMA) screening. Pretreatment <jats:sup>68<\/jats:sup>Ga-PSMA showed left sciatic nerve and multiple bone uptake. Patient underwent stereotactic radiotherapy on the sciatic nerve metastasis (30 Gy in 6 fractions of 5 Gy) before 7.4 GBq of <jats:sup>177<\/jats:sup>Lu-PSMA infusions. Left truncated sciatica disappeared after stereotactic radiotherapy. No additional toxicity was added to the sciatic nerve from <jats:sup>177<\/jats:sup>Lu-PSMA after stereotactic radiotherapy.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005503","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T22:02:23Z","timestamp":1728943343000},"page":"e668-e669","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis"],"prefix":"10.1097","volume":"49","author":[{"given":"David","family":"Tonnelet","sequence":"first","affiliation":[{"name":"Radiology and Nuclear Medicine Department, Henri Becquerel Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"Edet-Sanson","sequence":"additional","affiliation":[{"name":"Radiology and Nuclear Medicine Department, Henri Becquerel Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Cabourg","sequence":"additional","affiliation":[{"name":"Oncology Department, Clinique Mathilde"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Thureau","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Henri Becquerel Cancer Center, Rouen, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","year":"2024","journal-title":"Lancet Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.123.266391","article-title":"Differences and common ground in 177 Lu-PSMA radioligand therapy practice patterns: international survey of 95 theranostic centers","volume":"65","year":"2024","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.canrad.2021.08.007","article-title":"Guidelines for external radiotherapy and brachytherapy procedures: 3rd edition","volume":"26","year":"2022","journal-title":"Cancer Radiother"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","year":"2014","journal-title":"Prostate"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/JU.0000000000001131","article-title":"The impact of race and age on distribution of metastases in patients with prostate cancer","volume":"204","year":"2020","journal-title":"J Urol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1097\/RLU.0000000000002476","article-title":"68Ga-PSMA uptake in prostate cancer sciatic nerve metastasis","volume":"44","year":"2019","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:05:40Z","timestamp":1750532740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":8,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005503","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}